Newsflash

Press Release – NEURO-BIO ATTRACTS OVER $3 MILLION IN SERIES A INVESTMENT TO DEVELOP A NEW APPROACH TO ALZHEIMER’S DISEASE Click here for the Neuro-Bio press release

European Patent Granted

We are pleased to announce that the European Patent Office intends to grant our application for a patent – Neurodegenerative Disorders Neuro-Bio Ltd Application No. 14736948.2

Susan Greenfield’s upcoming talks

Friday 19 May 2017 at 10:00 – World Precision Medicine Congress 2017, Business Design Centre, 52 Upper Street, Islington, London N1 0QH – Precision medicine and neurodegenerative disease
Tuesday 6 June/Wednesday 7 June 2017 – OECD Forum Paris, France – Details still to be finalised

Congratulations!

Congratulations to Sara Garcia-Rates on her return from maternity leave and to Emily Smith whoa gave birth to Amelia in December      

BioNewsRound Award finalist!

Neuro-Bio Ltd are delighted to announce that we have been short listed for the BioNewsRound Award. Our CEO, Susan Greenfield will be presenting a short presentation at the ON Helix Welcome Reception on 27th June. You can find out more information on their website, here.

Alzheimer’s Disease: Defusing The Bomb By 2025

Published in In Vivo Beyond Beta-Amyloid  The US FDA has approved six drugs to treat Alzheimer’s symptoms, all of which work by increasing the amount of neurotransmitters in the brain, helping nerve cells in the brain to communicate. These approved therapies are: Razadyne (galantamine), Exelon (rivastigmine), Aricept, Namenda,Namzaric (memantine + donepezil) and Cognex, which is no longer widely sold in the US. None of these drugs prevent or treat the cause of Alzheimer’s, nor do they slow progression of the disease.